Focus on the workstreams: Patients as partners

21 June, 2019 | Posted in:

‘Supporting people with MS to understand and take control of their condition and how they manage it.’ Shift.ms are leading this workstream, with CEO George Pepper member of the ‘Raising the Bar’ steering group and Service designer Rob Sloan leading the workstream session. Objective: To develop an expert patient course designed by and for pwMS […]

Continue Reading »

Raising the bar for MS: patients as partners

21 June, 2019 | Posted in:

George Pepper, CEO of online ‘MSer’ community Shift.ms, talks to us about how we engage patients as meaningful partners in managing their condition and why this MS workstream will help tackle variance and raise the bar for people with MS. Shift.ms as a company are leading this workstream and George is a steering group representative […]

Continue Reading »

Focus on the workstreams: data

14 June, 2019 | Posted in:

Understanding and using available data to drive insight and change Dr David Rog, consultant neurologist at Salford Royal NHS Foundation Trust is the representative on the national ‘Raising the bar’ steering group and lead for this workstream. He will be joined by Hassan Chaudhury (Chief Commercial Officer, Health iQ) to co-chair the workstream meeting. Objectives: […]

Continue Reading »

Focus on the workstreams: Social determinants of health

7 June, 2019 | Posted in:

How can we as healthcare professionals address social determinants of health? Gavin Giovannoni, Professor of Neurology at Barts and The London is the chair for the national ‘Raising the bar’ steering group and the lead for this workstream. Dr Helen Ford, consultant neurologist and MSologist at Leeds Teaching Hospital, will co-chair the workstream. ‘The social […]

Continue Reading »

Raising the bar for MS: Social determinants of health

7 June, 2019 | Posted in:

Professor Gavin Giovannoni talks to us about the social determinants of health, and why this MS workstream will help tackle variance and raise the bar for people with MS. Gavin is the lead for this workstream – find out more about the workstream itself here or learn more about the background to this work. Why […]

Continue Reading »

Focus on the workstreams: Audit

7 June, 2019 | Posted in:

A pragmatic rolling UK MS audit: What data to collect and how to collect it painlessly Jeremy Hobart, Professor of Clinical Neurology and Health Measurement at Plymouth University Peninsula Schools of Medicine and Dentistry is the representative on the national ‘Raising the bar’ steering group and lead for this workstream. ‘Of course auditing will identify […]

Continue Reading »

Focus on the workstreams: Wellness and lifestyle

29 May, 2019 | Posted in:

How to incorporate wellness and lifestyle interventions into clinical practice Dr Agne Straukiene, consultant neurologist at Torbay and South Devon NHS Foundation Trust, is a representative on the national ‘Raising the bar’ steering group and the lead for this workstream. ‘I want my patients to live a long, healthy and present life. That’s why I’m […]

Continue Reading »

Raising the bar for MS: Health and wellbeing

29 May, 2019 | Posted in:

Dr Agne Straukiene talks to us about health and wellbeing, and why this MS workstream will help tackle variance and raise the bar for people with MS. Agne is the lead for this workstream – find out more about the workstream itself here or learn more about the background to this work. Why does ‘health […]

Continue Reading »

MS MasterClass 6.2 project winners announced!

17 May, 2019 | Posted in: ,

Last night, Olivia Moswela was announced the winner of the MS MasterClass project for our 6th MS intermodule project awards. Olivia, who presented her work on infectious complications of disease-modifying therapies (DMTs) in MS, had carried out an audit into both pre-treatment screening and risk mitigation for the high-efficacy treatments available in her locality. Runner-up […]

Continue Reading »

Ocrelizumab now available for those with primary progressive MS

10 May, 2019 | Posted in:

Ocrelizumab, the first disease-modifying treatment (DMT) to be proven in slowing down the progression of primary progressive multiple sclerosis (PPMS), has finally been signed off for use at a clinical level. The DMT has been licensed for relapsing-remitting (RR) MS for almost a year, but despite being the first drug to show efficacy in the […]

Continue Reading »